Articles related to RESEARCH & CLINICAL TRIALS

Switching Parkinson’s patients to Crexont added more than three hours of daily symptom control in interim Phase 4 data. Here’s how to read an open-label, sponsor-run signal.

The OSPREY trial puts proximal hypoglossal nerve stimulation on the map for moderate-to-severe OSA, with strong short-term numbers and the limitations a small unblinded RCT carries.

Daraxonrasib produced 13.2-month median overall survival versus 6.7 months with chemotherapy in 501 previously treated metastatic pancreatic ductal adenocarcinoma patients in the phase 3 RASolute 302 trial.

Osimertinib plus datopotamab deruxtecan produced 20.5-month median duration of response at the 6 mg/kg dose in EGFR-mutated NSCLC after first-line osimertinib progression in the ORCHARD platform substudy.

In two randomized phase‑3 trials, a single‑pill triple low‑dose antihypertensive combination achieved blood pressure reductions comparable to amlodipine and superior to losartan monotherapy over 8 weeks.

“Fluvoxamine may have a beneficial role in the clinical management of fatigue in long COVID, although the condition encompasses a broad range of clinical manifestations beyond fatigue alone.” — REVIVE Trial, Annals of Internal Medicine